InxMed presented preclinical data on ifebemtinib, revealing its potential to reduce fibrotic barriers around tumors, thereby enhancing the effectiveness and safety of antibody-drug conjugates (ADCs).
The data indicates that by inhibiting focal adhesion kinase (FAK), ifebemtinib can significantly improve the penetration of ADCs into solid tumors, especially those resistant to existing treatments.
InxMed's innovative approach targets cancer-associated fibroblasts to overcome limitations posed by tumor microenvironments, suggesting a promising strategy for enhancing ADC therapies.
The results from the Annual World ADC Conference highlight ifebemtinib's role as a potent oral inhibitor, potentially transforming the treatment landscape for fibrotic solid tumors.
Collection
[
|
...
]